Until now, doctors knew hepatic stellate cells mainly as drivers of liver fibrosis. The actual functions of this cell type have hardly been studied to date. Researchers have now determined that ...
Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder influenced by multiple genes, but their ...
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...
The global liver fibrosis treatment market is poised for substantial growth, with revenue projections increasing from USD 17.51 billion in 2024 to USD 51.16 billion by 2033. This expansion represents ...
Hepatic steatosis, often triggered by non-alcoholic fatty liver disease (NAFLD), is a leading cause of liver dysfunction globally, affecting approximately 30% of the population.
Hepatic stellate cells reside between the hepatocytes and small blood vessels ... leading to chronic fibrosis or cirrhosis. Liver fibrosis develops from excessive matrix produced by activated ...
Surrozen Inc, South San Francisco, United States Department of Interdisciplinary Oncology, Louisiana State University Health Science Center, New Orleans, United States Division of Gastroenterology and ...
In conclusion, new thresholds for APRI and FibroScan in the diagnosis of significant fibrosis and cirrhosis have been proposed and have informed the 2024 WHO hepatitis B guidelines, which are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback